The share price of drug distribution firm McKesson Corp (NYSE:MCK) has completely missed the recent stock market rally. Yet its operating fundamentals remain strong and health care reform efforts should breathe further life into its growth prospects.

IN PICTURES: World's Greatest Investors

First Quarter Review
First quarter sales ended June 30 and rose 3% to $27.5 billion. Core distribution revenue accounted for the vast majority of sales (97.2%) and reported a 3% increase. This area consists of acting as a middleman between pharmaceutical firms such as Merck (NYSE:MCK) and distributing drugs to hospitals and drugstores such as HMA (NYSE:HMA) and CVS Caremark (NYSE:CVS),

McKesson also operates a small but very profitable technology solutions segment that sells software and supply chain know-how to help its core customer base operate more efficiently. This unit only reported a 2% rise in the top line but accounted for 11.2% of total divisional operating profits.

Total company operating income was $474 million and grew 3% as gross profits improved but SG&A costs increase more rapidly than sales. Net income also improved 3% to $298 million, or $1.12 per diluted share.

Analysts currently project full-year sales growth of 3% to a hair under $112 billion. Management expects earnings between $4.72 and $4.92 per diluted share. However, net income tends to understate McKesson's impressive cash flow generation capabilities. For example, last year earnings were $4.58 but free cash flow exceeded $7 per diluted share.

The Bottom Line
McKesson's first quarter results were respectable and its cash flow generation has allowed for a steady stream of share buybacks and dividend increases. The balance sheet is also strong, with cash on hand in excess of long-term debt for a net cash position.

Yet for some reason, the share price has traded down significantly recently and is very close to its lows over the past year. The forward P/E is now only 12.3, if the company reaches the midpoint of its guidance. The free cash flow multiple will be much lower as long as McKesson continues to efficiently manage its working capital and keep capex low.

This is a very reasonable entry level given McKesson's operations continue to grow and healthcare reform efforts will add millions of new patients into the industry over the coming few years. Rival AmerisourceBergen (NYSE:ABC) is also worth a look, though its stock price has held up as of late. (Want more on evaluating medical companies? Check out Measuring The Medicine Makers.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  2. Investing News

    Ferrari’s IPO: Ready to Roll or Poor Timing?

    Will Ferrari's shares move fast off the line only to sputter later?
  3. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  4. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  5. Fundamental Analysis

    Use Options Data To Predict Stock Market Direction

    Options market trading data can provide important insights about the direction of stocks and the overall market. Here’s how to track it.
  6. Stock Analysis

    2 Oil Stocks to Buy Right Now (PSX,TSO)

    Can these two oil stocks buck the trend?
  7. Investing News

    What Alcoa’s (AA) Breakup Means for Investors

    Alcoa plans to split into two companies. Is this a bullish catalyst for investors?
  8. Stock Analysis

    Top 3 Stocks for the Coming Holiday Season

    If you want to buck the bear market trend by going long on consumer stocks, these three might be your best bets.
  9. Investing News

    Could a Rate Hike Send Stocks Higher?

    A rate hike would certainly alter the investment scene, but would it be for the better or worse?
  10. Investing News

    Corporate Bonds or Stocks: Which is Better Now?

    With market volatility high, you may think it is time to run for corporate bonds instead of stocks. Before you do take a deeper look into which is better.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!